A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK Plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

PURPOSE: Based on preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with previously treated advanced PDAC. EXPERIMENTAL DESIGN: I...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Cancer Res
Κύριοι συγγραφείς: Ko, Andrew H., Bekaii-Saab, Tanios, Van Ziffle, Jessica, Mirzoeva, Olga M., Joseph, Nancy, Talasaz, AmirAli, Kuhn, Peter, Tempero, Margaret A., Collisson, Eric A., Kelley, R. Kate, Venook, Alan P., Dito, Elizabeth, Ong, Anna, Ziyeh, Sharvina, Courtin, Ryan, Linetskaya, Regina, Tahiri, Sanaa, Korn, W. Michael
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2015
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703532/
https://ncbi.nlm.nih.gov/pubmed/26251290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0979
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια